ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

IMPACTS OF DOMPERIDONE IN AMALGAMATION WITH OMEPRAZOLE IN THERAPY OF CHRONIC SUPERFICIAL GASTRITIS

AUTHORS:

Dr Muhammad Faisal Shahzad, Dr Muhammad Awais Watoo, Dr Hafiz Rahil Asif

ABSTRACT:

Objective: This research work aimed to determine the impacts of domperidone with combination of omeprazole while treating the CSG (Chronic Superficial Gastritis). Methodology: Total 94 patients who were suffering from CSG and obtained treatment from Doctors Hospital, Lahore from August 2018 to August 2019 were the participants of this research work. We divided the patients into control and test group with forty-eight patients in each group with the utilization of the double blind procedure. We treated the patients of control group by omeprazole, whereas we treated the patients of test group by domperidone in collaboration with the omeprazole. We analyzed and observed the clinical impacts of the patients of both groups. Results: The symptoms scores were not different between the patients of both groups before the treatment. We saw the improvement of symptoms scores in the patients of test group superior as compared to the patients of control group after treatment (P < 0.050). We observed the overall response rate in the patients of test group as 97.920% (47 out of total 48) which was much higher as compared to the patients in control group (75%). After complete therapy, the repair impact of the gastric mucosa and recurrence rate after surgical intervention in the patients of test group was much high as compared to those present in the group of controls (P < 0.050). Conclusion: Domperidone in collaboration with omeprazole can attain ideal impacts in the therapy of chronic superficial gastritis. This is much important for the treatment and early prognosis of the patients. Keywords: CSG, methodology, prognosis, omeprazole, therapy, control.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.